Great interview. Key points for me were that Roger Aston believes a good outcome for the canine trials is to partner with Elanco and take monepantel to market market for a potential US$150-200 million cut of the US$500- 600 million pet cancer market p/a. (Of course PAA would receive a royalty from that potential $150-200m). Other key point was post successful trials, find a partner to co develop human applications for a slice of the US$52 billion chemotherapy market in humans.
Great interview. Key points for me were that Roger Aston...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.3¢ | $108.2K | 647.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 109170 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 117939 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |